Format

Send to

Choose Destination
See comment in PubMed Commons below
Microbes Infect. 2014 May;16(5):409-18. doi: 10.1016/j.micinf.2014.03.006. Epub 2014 Apr 1.

FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.

Author information

1
Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang 050017, China.
2
Third Hospital of Hebei Medical University, Shijiazhuang 050000, China.
3
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai 200032, China. Electronic address: shibojiang@fudan.edu.cn.
4
Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang 050017, China. Electronic address: weilin501@163.com.

Abstract

We report the construction of a recombinant multivalent vaccine against group A streptococcus (GAS), designated F7M5. It contains seven predominant epitopes of FbaA identified by phage display technology, five non-tissue cross-reactive M protein fragments expressed on four selected serotypes prevalent in China, a Trojan antigen (TA) and a poly-alanine DR epitope (PADRE). BALB/c mice were immunized subcutaneously with F7M5 formulated with Freund's adjuvant, using recombinant FbaA and M protein in parallel as control. Using enzyme-linked immunosorbent assay (ELISA), mouse immune sera were assayed for IgG titers, IgG subclasses, and binding of F7M5 with M1GAS. Results indicated that the multivalent vaccine was highly immunogenic and elicited a balanced IgG1/IgG2a response. We also tested the reactivity of F7M5 to antistreptolysin O (ASO) antibodies in sera of GAS-infected patients and found a 95.8% positive rate, indicating that the epitopes of the vaccine were widely expressed in the prevalent serotypes of GAS. More importantly, the F7M5 vaccine elicited strong protective immune responses against lethal-dose challenge with a survival rate of 90%, but induced no cross-reactions or pathological lesions in mouse model, suggesting that F7M5 can be further developed as an effective and safe anti-GAS vaccine.

KEYWORDS:

Epitope; FbaA; Group A streptococcus (GAS); M protein; Vaccine

PMID:
24704476
DOI:
10.1016/j.micinf.2014.03.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center